Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02066415 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention
A Phase 2 study of Treatment for Prevention of Chronic Migraine, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 667
- Enrollment target
- 20
- Study locations
NCT02066415: Completed Phase 2 study of Treatment for Prevention of Chronic Migraine, sponsored by Amgen.
NCT02066415 is a Phase 2 study of Treatment for Prevention of Chronic Migraine that has completed, run by Amgen. The registered enrollment target is 667 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (402% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02066415, a Phase 2 study of Treatment for Prevention of Chronic Migraine, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 667 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the effect of erenumab compared to placebo on the change from baseline in the number of monthly migraine days in adults with chronic migraine.
Primary Outcome
A migraine day was any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined either as a migraine with or without aura. The change from baseline in monthly migraine days was calculated as the number of migraine days during the last 4 weeks of the 12-week treatment phase - the number of migraine days during the 4-week baseline phase.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Erenumab
Study Locations (20)
California
- Research Site - La Jolla
- Research Site - Newport Beach
- Research Site - San Francisco
- Research Site - Santa Monica
- Research Site - Sherman Oaks
- Research Site - Stanford
Florida
- Research Site - Jacksonville
- Research Site - Orlando
- Research Site - Palm Beach Gardens
- Research Site - West Palm Beach
Georgia
- Research Site - Atlanta
- Research Site - Decatur
Massachusetts
- Research Site - Watertown
- Research Site - Worcester
Michigan
- Research Site - Ann Arbor
- Research Site - Kalamazoo
Connecticut
- Research Site - Stamford
Indiana
- Research Site - Indianapolis
Maryland
- Research Site - Pikesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 667 participants |
| Start Date | 2014-03-05 |
| Est. Completion | 2016-04-28 |
| Phase | Phase 2 |
What the finished NCT02066415 record still lists
NCT02066415 is an interventional study that assigns participants to a tested intervention. The registered 667 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (402% higher).
The record links to 1 condition, with Treatment for Prevention of Chronic Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02066415 names 20 study sites across 9 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT02066415 about?
NCT02066415 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention". To evaluate the effect of erenumab compared to placebo on the change from baseline in the number of monthly migraine days in adults with chronic migraine.
What is the current status of trial NCT02066415?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 667 participants. The study started on 2014-03-05. Estimated completion is 2016-04-28.
What conditions does trial NCT02066415 study?
This clinical trial studies the following conditions: Treatment for Prevention of Chronic Migraine.
What interventions are being tested in trial NCT02066415?
The interventions under investigation include: Placebo (DRUG), Erenumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02066415?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02066415 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02066415's enrollment target sits among peer trials
667 48th of 2000 higher than 1,953 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04155034 · 668 participants · Phase 3
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
- NCT04179981 · 668 participants · NA
Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)
- NCT05006482 · 668 participants · Phase 3
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
- NCT06328647 · 666 participants · NA
Quantra Point-of-Care Hemostasis Monitoring
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI